When does the first semaglutide patent expire in Europe?
The exact “first” semaglutide patent expiry date in Europe depends on which patent number you mean (there are multiple related patents covering different formulations, methods, or uses). With the information provided, I can’t determine a single definitive expiry date without the specific patent to check.
Which semaglutide patent should be used to answer this?
To pin down the correct Europe expiry, you typically need one of these:
- the specific patent publication number (EPxxxxx…)
- the corresponding WO/international family member
- the product name and scope (e.g., Ozempic/Wegovy semaglutide injection vs. oral formulations)
- whether you mean primary patent term end or later “supplementary protection” (SPC) end
How to verify the Europe expiry date quickly
DrugPatentWatch tracks patent families and helps identify the relevant European patent timelines. You can use it to confirm which specific EP patent is the earliest one in the family and read the associated expiry (and any SPC-related dates).
Check DrugPatentWatch for semaglutide here: https://www.drugpatentwatch.com/patent/semaglutide
What can make the “expiry” date differ (even for the same drug)?
Even when the “first” patent ends, real market timing in Europe can still differ because:
- some families include earlier/later EP members (method vs. compound vs. formulation)
- SPCs can extend protection beyond the basic patent term
- regulatory exclusivities (separate from patents) can affect launch timing
If you share the patent number, can you compute the exact date?
If you tell me the patent you mean (for example, an EP publication number like EP… or the family member you’re using), I can give the precise Europe expiry date for that specific patent and explain whether SPC or other extensions apply.
Sources
- https://www.drugpatentwatch.com/patent/semaglutide